Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
39
datasets available to search
ShareScore release 0.9.0
Dataset results
39 results for “injection drug users”
Intensive Models of HCV Care for Injection Drug Users
ClinicalTrials.gov study NCT01857245. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug Users
ClinicalTrials.gov study NCT00270257. IPD Sharing: NO. Countries: 2. Publications: 7.
Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users
ClinicalTrials.gov study NCT01741350. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
ClinicalTrials.gov study NCT00244374. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Data from: Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and non-injection drug users from coastal Kenya
Background: Information about HBV sero-markers, infection stages and genotypes in HIV-1 infected and uninfected injection and non-injection drug users (IDUs) in Kenya remains elusive. Methods: A cross-sectional study examining HBV sero-marker, infection stages and genotypes was conducted among HIV-1 infected and uninfected, respectively, IDUs (n = 157 and n = 214) and non-IDUs (n = 139 and n = 48), and HIV-1 uninfected non-drug using controls (n = 194) from coastal, Kenya. HBV sero-marker and infection stages were based on HBV 5-panel rapid test plasma sero-reactivity. DNA was extracted from acute and chronic plasma samples and genotypes established by nested-PCR and direct sequencing. Results: HBsAg positivity was higher in HIV-1 infected IDUs (9.6 %) relative to HIV-1 uninfected IDUs (2.3 %), HIV-1 infected non-IDUs (3.6 %), HIV-1 uninfected non-IDUs (0.0 %) and non-drug users (2.6 %; P = 0.002). Contrastingly, HBsAb positivity was higher in HIV-1 uninfected IDUs (14.6 %) and non-IDUs (16.8) in comparison to HIV-1 infected IDUs (8.3 %), and non-IDUs (8.6 %), and non-drug users (8.2 %; P = 0.023). HBcAb positivity was higher in HIV-1 infected IDUs (10.2 %) compared to HIV-1 uninfected IDUs (3.3 %), HIV-1 infected non-IDUs (6.5 %), HIV-1 uninfected non-IDUs (2.1 %) and non-drug users (4.6 %; P = 0.038). Acute (5.7 %, 1.4 %, 0.0 %, 0.0 % and 1.5 %) and chronic (5.1 %, 0.9 %, 3.6 %, 0.0 % and 1.5 %) stages were higher in HIV-1 infected IDUs, compared to HIV-1 uninfected IDUs, HIV-1 infected and uninfected non-IDUs and non-drug users, respectively. However, vaccine type response stage was higher in HIV-1 uninfected IDUs (15.4 %) relative to HIV-1 infected IDUs (6.4 %), and HIV-1 infected (6.5 %), and uninfected (10.4 %) non-IDUs, and non-drug users (5.7 %; P = 0.003). Higher resolved infection rates were also recorded in HIV-1 uninfected IDUs (11.2 %) compared to HIV-1 infected IDUs (8.3 %), and HIV-1 infected (7.2 %), uninfected (6.3 %) non-IDUs, and non-drug users (6.7 %; P = 0.479), respectively. Only A1 genotype showing minimal diversity was detected among the study participants. Conclusion: HBV sero-markers and infection staging are valuable in diagnosis and genotyping of HBV infections. Among IDUs, higher HBsAg and HBcAb positivity in HIV-1 infected and higher HBsAb positivity in HIV-1 negative IDUs suggests frequent exposure. Additionally, HBV genotype A is the dominant circulating genotype in both high and low risk populations of Kenya.
Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
ClinicalTrials.gov study NCT01448915. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users
ClinicalTrials.gov study NCT01334736. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Swedish Prison Program is an Intervention Prevention Program Targeting Injecting Drug Users Risk Behaviours and Infectious Diseases
ClinicalTrials.gov study NCT02234167. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Peer Leaders as HIV Risk Reduction Change Agents Among Injection Drug Users (IDUs) in Ukraine
ClinicalTrials.gov study NCT01159704. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Behavioral Intervention Trial for HIV-infected Injection Drug Users
ClinicalTrials.gov study NCT00146445. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Behavioral Intervention for HIV and HCV-Uninfected Injection Drug Users
ClinicalTrials.gov study NCT00164372. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Preventing Bacterial and Viral Infections Among Injection Drug Users
ClinicalTrials.gov study NCT01892358. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Linking Hospitalized Injection Drug Users to Buprenorphine
ClinicalTrials.gov study NCT00987961. IPD Sharing: Not stated. Countries: 1. Publications: 2.
HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of Biomarkers
ClinicalTrials.gov study NCT00491335. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Improving Hepatitis C Treatment in Injection Drug Users
ClinicalTrials.gov study NCT00148031. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Correlates and Consequences of Increased Immune Activation in Injection Drug Users
ClinicalTrials.gov study NCT01831284. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users
ClinicalTrials.gov study NCT05886504. IPD Sharing: NO. Countries: 1. Publications: 0.
A Trial to Reduce Hepatitis C Among Injection Drug Users - 1
ClinicalTrials.gov study NCT00218192. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China
ClinicalTrials.gov study NCT01647191. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Hepatitis B virus sero-profiles and genotypes in HIV-1 infected and uninfected injection and non-injection drug users from coastal Kenya
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.